Testosterone deficiency and cardiovascular mortality

Asian Journal of Andrology

Volumn 17, Issue 1, 2015, Pages 26-31

  Morgentaler, Abraham ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

cardiovascular; mortality; myocardial infarction; risk; stroke; testosterone

Indexed keywords

TESTOSTERONE;

ANDROGEN DEFICIENCY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; FAT MASS; GLYCEMIC CONTROL; HUMAN; MALE; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TESTOSTERONE BLOOD LEVEL; ADVERSE EFFECTS; BLOOD; CARDIOVASCULAR DISEASES; DEFICIENCY; ERECTILE DYSFUNCTION; HORMONE SUBSTITUTION; MORTALITY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE;

CARDIOVASCULAR DISEASES; DRUG PRESCRIPTIONS; ERECTILE DYSFUNCTION; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; RISK FACTORS; SURVIVAL RATE; TESTOSTERONE;

EID: 84920390262     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.143248     Document Type: Review

References (64)

1. Baillargeon J, Urban RJ, Ottenbacher KJ, Pierson KS, Goodwin JS. Trends in androgen prescribing in the United States, 2001 to 2011. JAMA Intern Med 2013; 173: 1465-6.
2. Kelly DM, Jones TH. Testosterone and cardiovascular risk in men. Front Horm Res 2014; 43: 1-20.
3. Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A, et al. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab 2002; 87: 3632-9.
4. Morgentaler A. Goodbye androgen hypothesis, hello saturation model. Eur Urol 2012; 62: 765-7.
5. Khera M, Crawford D, Morales A, Salonia A, Morgentaler A. A new era of testosterone and prostate cancer: from physiology to clinical implications. Eur Urol 2014; 65: 115-23.
6. Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014; 9: e85805.
7. Vigen R, O'Donnell CI, Barón AE, Grunwald GK, Maddox TM, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013; 310: 1829-36.
8. Fernández-Balsells MM, Murad MH, Lane M, Lampropulos JF, Albuquerque F, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95: 2560-75.
9. Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloña ER, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007; 82: 29-39.
10. Carson CC 3 rd, Rosano G. Exogenous testosterone, cardiovascular events, and cardiovascular risk factors in elderly men: a review of trial data. J Sex Med 2012; 9: 54-67.
11. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, et al. Executive summary: heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014; 129: 399-410.
12. Khaw KT, Dowsett M, Folkerd E, Bingham S, Wareham N, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007; 116: 2694-701.
13. Haring R, Völzke H, Steveling A, Krebs A, Felix SB, et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J 2010; 31: 1494-501.
14. Araujo AB, Kupelian V, Page ST, Handelsman DJ, Bremner WJ, et al. Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med 2007; 167: 1252-60.
15. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, et al. Clinical review: endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96: 3007-19.
16. Corona G, Rastrelli G, Monami M, Guay A, Buvat J, et al. Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol 2011; 165: 687-701.
17. Dobrzycki S, Serwatka W, Nadlewski S, Korecki J, Jackowski R, et al. An assessment of correlations between endogenous sex hormone levels and the extensiveness of coronary heart disease and the ejection fraction of the left ventricle in males. J Med Invest 2003; 50: 162-9.
18. Rosano GM, Sheiban I, Massaro R, Pagnotta P, Marazzi G, et al. Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J Impot Res 2007; 19: 176-82.
19. Hu X, Rui L, Zhu T, Xia H, Yang X, et al. Low testosterone level in middle-aged male patients with coronary artery disease. Eur J Intern Med 2011; 22: e133-6.
20. Mäkinen J, Järvisalo MJ, Pöllänen P, Perheentupa A, Irjala K, et al. Increased carotid atherosclerosis in andropausal middle-aged men. J Am Coll Cardiol 2005; 45: 1603-8.
21. Morgentaler A. ASG Urges FDA to Deny Petition for Black Box Warning. Androgen Study Group (ASG) 2014. Available from: http://www.androgenstudygroup.org/initiatives/letter-to-fda-asking-to-deny-black-box-petition. [Last accessed on 2014 Jul 02].
22. Xu S, Shetterly S, Powers D, Raebel MA, Tsai TT, et al. Extension of Kaplan-Meier methods in observational studies with time-varying treatment. Value Health 2012; 15: 167-74.
23. Correction. "Incorrect Language." JAMA 2014; 311: 306. Available from: http://www.jama.jamanetwork.com/article.aspx?articleid=1814192. [Last accessed on 2014 Apr 26].
24. "Incorrect Number of Excluded Patients Reported in the Text and Figure." JAMA 2014; 311: 967. Available from: http://www.jama.jamanetwork.com/article.aspx?articleid=1835478. [Last accessed on 2014 Apr 26].
25. Morgentaler A. Letter to JAMA Asking for Retraction of Misleading Article on Testosterone Therapy, Androgen Study Group (ASG) 2014. Available from: http://www.androgenstudygroup.org/initiatives/letter-to-jama-asking-for-retraction-of-misleading-article-on-testosterone-therapy. [Last accessed on 2014 Jul 02].
26. NIH. Risk Assessment Tool for Estimating Your 10-year Risk of Having a Heart Attack. Available from: http://www.cvdrisk.nhlbi.nih.gov/calculator.asp. [Last accessed on 2014 Apr 21].
27. Muraleedharan V, Marsh H, Kapoor D, Channer KS, Jones TH. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol 2013; 169: 725-33.
28. Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 2012; 97: 2050-8.
29. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363: 109-22.
30. Srinivas-Shankar U, Roberts SA, Connolly MJ, O'Connell MD, Adams JE, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010; 95: 639-50.
31. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med 2013; 11: 108.
32. Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 2005; 60: 1451-7.
33. Schwartz LM, Woloshin S. Low "T" as in "template": how to sell disease. JAMA Intern Med 2013; 173: 1460-2.
34. Ho PM, Barón AE, Wierman ME. Deaths and cardiovascular events in men receiving testosterone-reply. JAMA 2014; 311: 964-5.
35. Morgentaler A, Traish A, Kacker R. Deaths and cardiovascular events in men receiving testosterone. JAMA 2014; 311: 961-2.
36. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 2000; 102: 1906-11.
37. Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005; 63: 280-93.
38. Aversa A, Bruzziches R, Francomano D, Rosano G, Isidori AM, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 2010; 7: 3495-503.
39. Francomano D, Lenzi A, Aversa A. Effects of five-year treatment with testosterone undecanoate on metabolic and hormonal parameters in ageing men with metabolic syndrome. Int J Endocrinol 2014; 2014: 527470.
40. Hackett G, Cole N, Bhartia M, Kennedy D, Raju J, et al. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. J Sex Med 2014; 11: 840-56.
41. Haider A, Saad F, Doros G, Gooren L. Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: an observational study. Obes Res Clin Pract 2014; 8: e339-49.
42. Haider A, Yassin A, Doros G, Saad F. Effects of long-term testosterone therapy on patients with "diabesity": results of observational studies of pooled analyses in obese hypogonadal men with type 2 diabetes. Int J Endocrinol 2014; 2014: 683515.
43. Saad F, Haider A, Doros G, Traish A. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring) 2013; 21: 1975-81.
44. Traish AM, Haider A, Doros G, Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract 2014; 68: 314-29.
45. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004; 89: 2085-98.
46. Yassin A, Doros G. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clin Obes 2013; 3: 73-83.
47. Traish AM, Haider A, Doros G, Saad F. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract 2014; 68: 314-29.
48. Heufelder AE, Saad F, Bunck MC, Gooren L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009; 30: 726-33.
49. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011; 34: 828-37.
50. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003; 6: 1-7.
51. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154: 899-906.
52. Mårin P, Krotkiewski M, Björntorp P. Androgen treatment of middle-aged, obese men: effects on metabolism, muscle and adipose tissues. Eur J Med 1992; 1: 329-36.
53. Marin P. Testosterone and regional fat distribution. Obes Res 1995; 3 Suppl 4: 609S-12.
54. Hoyos CM, Yee BJ, Phillips CL, Machan EA, Grunstein RR, et al. Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial. Eur J Endocrinol 2012; 167: 531-41.
55. Naharci MI, Pinar M, Bolu E, Olgun A. Effect of testosterone on insulin sensitivity in men with idiopathic hypogonadotropic hypogonadism. Endocr Pract 2007; 13: 629-35.
56. Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009; 54: 919-27.
57. Malkin CJ, Jones TH, Channer KS. The effect of testosterone on insulin sensitivity in men with heart failure. Eur J Heart Fail 2007; 9: 44-50.
58. Strollo F, Strollo G, Morè M, Magni P, Macchi C, et al. Low-intermediate dose testosterone replacement therapy by different pharmaceutical preparations improves frailty score in elderly hypogonadal hyperglycaemic patients. Aging Male 2013; 16: 33-7.
59. Juang PS, Peng S, Allehmazedeh K, Shah A, Coviello AD, et al. Testosterone with dutasteride, but not anastrazole, improves insulin sensitivity in young obese men: a randomized controlled trial. J Sex Med 2014; 11: 563-73.
60. Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH, et al. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 2010; 96: 1821-5.
61. Menke A, Guallar E, Rohrmann S, Nelson WG, Rifai N, et al. Sex steroid hormone concentrations and risk of death in US men. Am J Epidemiol 2010; 171: 583-92.
62. Vikan T, Schirmer H, Njølstad I, Svartberg J. Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromsø Study. Eur J Endocrinol 2009; 161: 435-42.
63. Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008; 93: 68-75.
64. Shores MM, Matsumoto AM, Sloan KL, Kivlahan DR. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006; 166: 1660-5.